Recent Advances in Nanodelivery Systems for Plant and Food Derivatives, 2nd Edition

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 20 May 2025 | Viewed by 1663

Special Issue Editors


E-Mail Website
Guest Editor
Department of Chemistry “Ugo Schiff”, University of Florence, Via Ugo Schiff 6, 50019 Sesto Fiorentino, FI, Italy
Interests: natural products; drug delivery systems; nanocarriers; topical administration; oral administration; brain delivery
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Chemistry “Ugo Schiff”, University of Florence, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy
Interests: pharmaceutical technology; nanodelivery system; dermal and mucosal delivery; natural product formulation
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 103, 41125 Modena, Italy
Interests: NMR; food chemistry; functional foods; food authentication; metabolomics; analytical chemistry; chromatography; chemometrics; drug delivery systems
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue aims to collect contributions in the field of pharmaceutical nanotechnology applied to plant and food derivatives, also considering the possibility of using plant and food as a source of bioactive components of nanodelivery systems.

Many constituents of plants and foods have numerous biological activities, but they do not possess drug-like characteristics, with consequently limited efficacy and clinical use. Recently, many food macromolecules have been reported for health-promoting effects, but they have low application in functional foods, food supplements, medical devices, or medicine because of their inefficient systemic delivery and poor oral bioavailability. However, they have attracted considerable attention as structural components of nanocarriers due to their biocompatibility, biodegradability, renewable origin, and easy modification.

Therefore, nanotechnology encases the prospective of offering many strategies to improve the efficacy of natural derivatives from plants and foods and an application platform for their chemical, nutritional, and pharmaceutical potential.

Prof. Dr. Anna Rita Bilia
Dr. Giulia Vanti
Dr. Eleonora Truzzi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanodelivery system
  • liposome
  • nanovesicle
  • nanoparticle
  • nanoemulsion
  • food-macromolecule-based nanodelivery systems
  • bioavailability
  • controlled release
  • natural products
  • functional food
  • food supplements
  • plant derivatives
  • herbal drugs

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

22 pages, 2800 KiB  
Article
Clinical and Market Analysis of NanoBEO: A Public-Worth, Innovative Therapy for Behavioral and Psychological Symptoms of Dementia (BPSD)—Emerging Evidence and Its Implications for a Health Technology Assessment (HTA) and Decision-Making in National Health Systems
by Damiana Scuteri, Daniele Pierobon, Martina Pagliaro, Kengo Hamamura, Takafumi Hayashi, Loris Pignolo, Pierluigi Nicotera, Giacinto Bagetta and Maria Tiziana Corasaniti
Pharmaceutics 2024, 16(10), 1253; https://doi.org/10.3390/pharmaceutics16101253 - 27 Sep 2024
Viewed by 1108
Abstract
Background: According to scientific literature, some 99% of patients affected by Alzheimer’s disease (AD) suffer from behavioral and psychological symptoms of dementia (BPSD), also known as neuropsychiatric symptoms (NPSs). In particular, agitation is one of the most difficult disorders to treat. States of [...] Read more.
Background: According to scientific literature, some 99% of patients affected by Alzheimer’s disease (AD) suffer from behavioral and psychological symptoms of dementia (BPSD), also known as neuropsychiatric symptoms (NPSs). In particular, agitation is one of the most difficult disorders to treat. States of agitation represent a very serious problem as they make these subjects dangerous for themselves and others and worsen as the disease advances. To date, there are no specific solutions for treating agitation. The only authorized drug is risperidone (as well as brexpiprazole, approved by the FDA on 11 May 2023), which can be used for no longer than 6–12 weeks because it increases the risk of death—owing to cardiocerebrovascular accidents—by 1.6–1.7 times. Methods: In order to address the latter noteworthy unmet medical need, NanoBEO was produced. The aim of the present work is to generate the health technology assessment (HTA) of this nanotechnological device. The latter consists of a controlled release system, based on solid lipid nanoparticles loaded with bergamot essential oil (BEO). Results: The results of the present research assessed the current evidence in the field of non-pharmacological treatments for this condition, including relevant primary preclinical and clinical data studies supporting the use of this device and the production of the operative plan for its launch on the market. The findings offer recommendations for decision-making on its implementation in dementia. Conclusions: NanoBEO represents a public-worth innovation in this neglected area, marking a significant advancement in the history of dementia, moving from academic research to product development. Full article
Show Figures

Figure 1

Back to TopTop